Mirati Therapeutics CEO Charles Baum's 2018 pay jumps 200% to $4.9M
Mirati Therapeutics reports 2018 executive compensation
By ExecPay News
Published: April 19, 2019
Mirati Therapeutics reported fiscal year 2018 executive compensation information on April 19, 2019.
In 2018, five executives at Mirati Therapeutics received on average a compensation package of $2.7M, a 216% increase compared to previous year.
Average pay of disclosed executives at Mirati Therapeutics
Charles M. Baum, Chief Executive Officer, received $4.9M in total, which increased by 200% compared to 2017. 79% of Baum's compensation, or $3.9M, was in option awards. Baum also received $435K in non-equity incentive plan, $580K in salary, as well as $2.5K in other compensation.
James Christensen, Chief Scientific Officer, received a compensation package of $3.2M, which increased by 362% compared to previous year. 80% of the compensation package, or $2.6M, was in option awards.
Chris LeMasters, Executive Vice President and Chief Business Officer, earned $1.9M in 2018, a 285% increase compared to previous year.
Isan Chen, Executive Vice President and Chief Medical and Development Officer, received $1.7M in 2018, which increases by 128% compared to 2017.
Jamie A. Donadio, Chief Financial Officer, earned $1.6M in 2018, a 150% increase compared to previous year.
Related executives
Charles Baum
Mirati Therapeutics
Chief Executive Officer
Isan Chen
Mirati Therapeutics
Executive Vice President and Chief Medical and Development Officer
James Christensen
Mirati Therapeutics
Chief Scientific Officer
Jamie Donadio
Mirati Therapeutics
Chief Financial Officer
Chris LeMasters
Mirati Therapeutics
Former Executive Vice President and Chief Business Officer
You may also like
Source: SEC filing on April 19, 2019.